Qiagen reveals purchase price for Enzymatics buy; BioFire Diagnostics gets FDA blessing for updated PCR system;

> Qiagen ($QGEN) disclosed in a regulatory filing that it paid $114.2 million in cash to purchase Enzymatics' enzyme unit in December 2014. Filing

> bioMérieux's BioFire Diagnostics division got an FDA nod and European approval for an updated version of its FilmArray PCR molecular diagnostic system, FilmArray 2.0. Statement (PDF)

> Myriad Genetics ($MYGN) is touting promising clinical data for its melanoma test, saying the tool demonstrates 90% accuracy in distinguishing between benign skin moles from malignant melanoma. Statement

> India's Thyrocare Technologies, which touts itself as the "world's largest thyroid testing laboratory," is planning to raise $85 million to $100 million in an IPO by the end of June. Story

> Meridian Bioscience ($VIVO) snagged a CE mark for its new test for Streptococcus pneumoniae in urine and spinal fluid. Release

> Transgenomic priced its public offering, planning to raise $6.2 million in proceeds to fund working capital and general corporate purposes. Filing

> Thermo Fisher Scientific ($TMO) last year took on $155.7 million in charges related to job cuts, the company revealed in a regulatory filing. Filing

> Singapore-based diagnostics outfit Vela Diagnostics is ceasing normal operations, going into judicial management amid financial struggles. More

> Belgium-based OncoDNA inked a distribution agreement with BioSequence, making the latter the exclusive Spanish distributor of OncoDNA's clinical oncology molecular diagnostics. More

And Finally… A lack of conclusive testing for chronic fatigue syndrome could lead to a lack of consensus in the medical community on how to address the disease. Story (sub. req.)

Suggested Articles

LabCorp, Philips and Mount Sinai are coming together to develop an AI-driven pathology center of excellence, aimed initially at cancer diagnosis.

The FDA followed through with plans to end its Alternative Summary Reporting program, making 20 years’ worth of device safety data publicly available.

Janssen tapped Resolution Bioscience to develop a companion diagnostic for Zejula in patients with metastatic castration-resistant prostate cancer.